This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Written by Dr. Parmis Mojarab, DO·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed July 12, 2026·Methodology v1.0

Compounded GLP-1 legality in 2026: the timeline that closed the market

Quick answer

Routine compounding of semaglutide and tirzepatide is no longer lawful on the basis that created the market. The shortage exception closed when the FDA declared both shortages resolved, and enforcement discretion ended for every class of compounder between February 18 and May 22, 2025. On April 30, 2026 the FDA proposed closing the remaining 503B route as well.

The exact timeline

FDA compounding timeline for semaglutide and tirzepatide — every date sourced to an FDA order or court decision
Date	What happened	Why it matters
March 2022	Semaglutide (Wegovy) added to the FDA drug shortage list.	Shortage begins — the legal window for compounding opens.
August 2022	Ozempic (semaglutide) added to the shortage list.
December 15, 2022	Tirzepatide (Mounjaro, Zepbound) added to the shortage list.	Compounded tirzepatide becomes lawful under the shortage exception.
October 2, 2024	FDA declares the tirzepatide shortage resolved.	The legal basis for compounding tirzepatide as an 'essentially a copy' drug begins to close.
December 19, 2024	FDA reaffirms the tirzepatide resolution in a declaratory order.	Sets a 60-day (503A) / 90-day (503B) transition.
February 18, 2025	503A enforcement discretion for tirzepatide ENDS.	State-licensed pharmacies must stop compounding tirzepatide copies.
February 21, 2025	FDA removes semaglutide from the shortage list.
March 19, 2025	503B enforcement discretion for tirzepatide ENDS.	Outsourcing facilities must stop compounding tirzepatide copies.
April 22, 2025	503A enforcement discretion for semaglutide ENDS.
April 24, 2025	Court denies the Outsourcing Facilities Association's injunction (semaglutide).	OFA v. FDA, N.D. Tex. — FDA's determination stands.
May 7, 2025	Court upholds FDA on tirzepatide in OFA v. FDA.	The shortage-exception route is closed for both molecules.
May 22, 2025	503B enforcement discretion for semaglutide ENDS.	All shortage-based compounding of both molecules is now outside enforcement discretion.
April 30, 2026	FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.	Finding: no clinical need for outsourcing facilities to compound them from bulk. Comment period closed June 29, 2026.

The rule that governs everything

The "essentially a copy" rule

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act bar compounders from producing drugs that are essentially a copy of a commercially available FDA-approved product. While a drug sits on the FDA shortage list, that bar is lifted. Once the shortage is resolved, it snaps back.

Why every provider suddenly sells "personalized" and "microdose" doses

With the shortage exception gone, one narrow route remains open to 503A pharmacies: a compounded product is not considered 'essentially a copy' if the prescriber determines, and documents on the prescription, that the change produces a significant clinical difference for that individual patient. This is the legal mechanism — not a clinical breakthrough — behind the sudden, industry-wide appearance of "personalized dosing" and "microdose" GLP-1 programs. Changing the strength so it is not "the same, similar, or easily substitutable" as an approved dose is what keeps the product outside the copy definition.

Patients should understand what that means in practice: the dose you are offered may have been chosen partly to satisfy a regulatory test, not purely a clinical one. FDA's own guidance gives examples of a genuine clinical difference — removing an inactive ingredient because of a documented patient allergy, or switching a tablet to a liquid for a patient who cannot swallow — and expressly notes such changes are not necessarily applicable to GLP-1 drugs. That is a pointed signal about how much weight the agency gives this workaround.

What is still lawful

Two narrow routes remain. First, a 503A pharmacy may compound where the prescriber documents a significant clinical difference for that individual patient — the basis for 'personalized' and 'microdose' programmes. Second, genuine patient-specific needs, such as removing an excipient a patient is allergic to. FDA has pointedly noted that its own examples of a legitimate clinical difference are not necessarily applicable to GLP-1 drugs.

What is not lawful is what built the industry: mass-producing standard-strength copies of Wegovy and Zepbound and selling them as a cheaper equivalent.

Enforcement and litigation

Enforcement and litigation riskEli Lilly and Novo Nordisk are actively litigating against telehealth companies, medical spas and compounding pharmacies marketing compounded copies, and have sent cease-and-desist letters across the sector. Enforcement risk is not theoretical, and it falls on the provider — but a provider that is forced to stop mid-course leaves the patient without continuity of supply.

What this means for you as a patient

The risk you carry is not legal — it is continuity. If your pharmacy is forced to stop, your supply stops, potentially mid-titration. Ask any provider what their contingency is, and note that the brand price collapse has narrowed the reason to take that risk at all.

The finding most comparison sites will not printThe economic case for compounded GLP-1 has narrowed sharply, and almost no comparison site says so. In 2023 the choice was roughly $1,000+/month for brand versus $150–$300 for compounded — a gap wide enough to justify real regulatory risk. As of July 12, 2026, brand Zepbound is $299–$449 through LillyDirect, brand Wegovy is $349 (or $149 for the oral tablet) through NovoCare, and both drop to roughly $25 with commercial coverage. Meanwhile compounded programs advertise $99–$299.

For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.

Frequently asked questions

Is compounded tirzepatide legal in 2026?

Not on the basis that made it a mass-market product. The shortage exception closed and enforcement discretion ended in early 2025. The remaining 503A route requires a prescriber-documented clinical difference for the individual patient, which is what 'personalized dosing' is.

Did compounded GLP-1 become permanently legal through 503A and 503B?

No. That claim, which appears on several comparison sites, is wrong. Federal law bars compounding drugs that are essentially copies of approved products, and the exception that suspended that bar ended with the shortages.

Could this change again?

Yes. Litigation is ongoing and the FDA's 503B bulks-list proposal was still in process after its June 29, 2026 comment deadline. Treat any page on this topic, including ours, as time-sensitive.

Sources

U.S. Food and Drug Administration — labels and safety communications.
Peer-reviewed clinical trials cited above.
Our methodology and medical review policy.

Spotted an error? Submit a correction.